Companies: 10,795·Total market cap: $144.5T
Orchard Therapeutics plc

Orchard Therapeutics plc

ORTXNASDAQHealthcare
$16.70
+$0.05(+0.30%)
Market Cap$380108700
P/E Ratio—
52W High$16.72
52W Low$4.24
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Orchard Therapeutics plc (ORTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001748907 · ORTX · NASDAQ · as of Jun 9, 2026

Filing snapshot

339
Total Filings
SC 13G/A
Latest Form
2024-11-14
Most Recent
2018
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001748907 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-03-14
Fiscal Year End
Mar 14, 2023
Accession No.
0000950170-23-007708
Primary Document
ortx-20221231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001748907 · Accession 0000950170-23-007708

Latest Key Filings

6-KQuarterly Report
6-K
2019-12-02
View 6-K on SEC
8-KCurrent Report
8-K
2024-01-24Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2024-11-14
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-11-14
View
SC 13GBeneficial Ownership Report
SC 13G
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-02-12
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-02-09
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-02-08
View
15-12G15-12G
15-12G
2024-02-05
View
EFFECTEFFECT
EFFECT
2024-01-30
View
EFFECTEFFECT
EFFECT
2024-01-30
View
S-8 POSS-8 POS
S-8 POS
2024-01-24
View
S-8 POSS-8 POS
S-8 POS
2024-01-24
View
S-8 POSS-8 POS
S-8 POS
2024-01-24
View
S-8 POSS-8 POS
S-8 POS
2024-01-24
View
S-8 POSS-8 POS
S-8 POS
2024-01-24
View
Showing 1–15 of 274 filingsForm 4 / 144 hidden· 339 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001748907  |  Exchange: NASDAQ · Healthcare

Orchard Therapeutics plc (NASDAQ: ORTX) has submitted 339 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2018. As a Healthcare sector company with CIK 0001748907, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Orchard Therapeutics plc's most comprehensive regulatory disclosure. The most recent Orchard Therapeutics plc 10-K was filed on 2023-03-14 for fiscal year ending 2023. Historical ORTX 10-K annual reports are available from 2018 through 2023.

Investors researching Orchard Therapeutics plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
CLYM SEC Filings →CTEV SEC Filings →ITOS SEC Filings →SLGC SEC Filings →YMAB SEC Filings →RVNC SEC Filings →GTHX SEC Filings →VIGL SEC Filings →
→ ORTX Financials→ ORTX Earnings→ ORTX Insider Trades

Frequently Asked Questions

ORTX SEC Filings · 8 questions

Orchard Therapeutics plc (ORTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 339 filings and access original documents at no cost. Orchard Therapeutics plc's CIK is 0001748907.

ORTX SEC filingsOrchard Therapeutics plc SEC documentsfind ORTX 10-K